Parkinson's inflammation mystery: brain scans after mild immune trigger
NCT ID NCT05205291
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 45 times
Summary
This study aims to understand how inflammation in the brain works in Parkinson's disease. Researchers will give a mild inflammatory compound (LPS) to 30 volunteers—some with Parkinson's, some with a sleep disorder linked to Parkinson's, and some healthy—and use special PET-MR brain scans to see how the brain's immune cells respond. The goal is to learn more about the role of inflammation in Parkinson's, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Exeter
RECRUITINGExeter, United Kingdom
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lipopolysaccharide (LPS) and [11C]PBR28 tracer
What this could lead to
If successful, this could help explain how inflammation contributes to Parkinson's disease, potentially pointing toward new treatment targets.
What could go wrong
This is a very early, small study (30 people) focused on understanding mechanisms, not testing a treatment. The findings may not lead directly to new therapies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.